1 The pharmacological pro®le was studied of MEN 11420, or cyclo{[Asn(b-D-GlcNAc)-Asp-Trp-Phe-Dap-Leu]cyclo(2b-5b)}, a glycosylated derivative of the potent, selective, conformationally-constrained tachykinin NK 2 receptor antagonist MEN 10627 (cyclo(Met-Asp-Trp-Phe-Dap-Leu)cyclo(2b-5b)). 2 MEN 11420 competitively bound with high anity to the human NK 2 receptor stably transfected in CHO cells, displacing radiolabelled [ 125 I]-neurokinin A and [ 3 H]-SR 48968 with K i values of 2.5+0.7 nM (n=6) and 2.6+0.4 nM (n=3), respectively. 3 MEN 11420 showed negligible binding anity (pIC 50 56) at 50 dierent receptors (including tachykinin NK 1 and NK 3 receptors) and ion channels. 4 In the rabbit isolated pulmonary artery and rat urinary bladder MEN 11420 potently and competitively antagonized tachykinin NK 2 receptor-mediated contractions (pK B =8.6+0.07, n=10, and 9.0+0.04, n=12; Schild plot slope=71.06 (95% c.l.=71.3; 70.8) and 71.17 (95% c.l.=71.3; 71.0), respectively). MEN 11420 produced an insurmountable antagonism at NK 2 receptors in the hamster trachea and mouse urinary bladder. However, in both preparations, the eect of MEN 11420 was reverted by washout and an apparent pK B of 10.2+0.14, n= 9, and 9.8+0.15, n=9, was calculated in the hamster trachea and mouse urinary bladder, respectively. 5 MEN 11420 showed low anity (pK B 56) at guinea-pig and rat tachykinin NK 1 (guinea-pig ileum and rat urinary bladder) and NK 3 (guinea-pig ileum and rat portal vein) receptors. On the whole, the anities (potency and selectivity) showed by MEN 11420 for dierent tachykinin receptors, measured either in binding or in functional bioassays, were similar to those shown by the parent compound, MEN 10627. 6 The in vivo antagonism of the contractions produced by [bAla 8 ]neurokinin A(4 ± 10) (1 nmol kg 71 ) was observed after intravenous (dose range: 1 ± 10 nmol kg 71 ), intranasal (3 ± 10 nmol kg 71 ), intrarectal (30 ± 100 nmol kg 71 ) and intraduodenal (100 ± 300 nmol kg 71 ) administration of MEN 11420. MEN 11420 was more potent (about 10 fold) and longer lasting than its parent compound MEN 10627, possibly due to a greater metabolic stability. 7 A dose of MEN 11420 (100 nmol kg 71 , i.v.), that produced potent and long lasting inhibition of the contraction of the rat urinary bladder induced by challenge with the NK 2 selective receptor agonist [bAla 8 ]neurokinin A(4 ± 10) (10 ± 300 nmol kg 71 ), was without eect on the responses produced by the NK 1 receptor selective agonist [Sar 9 ]substance P sulphone (1 ± 10 nmol kg 71 ). 8 These ®ndings indicate that MEN 11420 is a potent and selective tachykinin NK 2 receptor antagonist. The introduction of a sugar moiety did not produce major changes in the anity pro®le of this antagonist as compared to MEN 10627, but markedly improved its in vivo potency and duration of action. With these characteristics, MEN 11420 is a suitable candidate for studying the pathophysiological signi®cance of tachykinin NK 2 receptors in humans.
Introduction
Neurokinin A (NKA), a member of the tachykinin peptide family, is widely distributed in the mammalian central and peripheral nervous systems: in the latter, NKA exerts its biological eects mainly by activating the tachykinin NK 2 receptor (Buck et al., 1984; Lee et al., 1986; Masu et al., 1987; Regoli et al., 1987) . Tachykinin NK 2 receptor antagonists are potential candidates for the treatment of bronchial hyperreactivity, irritable bowel syndrome, cystitis and other pathological conditions putatively mediated by endogenous tachykinins: this has prompted the search for potent and selective NK 2 receptor antagonists as drug candidates (Maggi et al., 1993; Quartara et al., 1995 for reviews) .
In our search for potent and selective tachykinin NK 2 receptor antagonists, we speculated that a common conformational feature should be present in NK 2 receptor agonists, such as [bAla 8 ]NKA(4 ± 10) (Saviano et al., 1991) , and certain peptide-derived antagonists, such as the cyclic hexapeptide L-659-877 (cyclo(Leu-Gln-Tpr-Phe-Gly-Met), Williams et al., 1988; Giolitti & Maggi, 1994) . From molecular modelling studies we postulated that a b-turn around the Trp-Phe segment would be important for high anity ligand-receptor interaction: on this basis, a conformational constraint which could lock the hypothetically active conformation in the monocyclic NK 2 receptor antagonist L-659-877 was designed (Pavone et al., 1995a,b) . The resulting compound, MEN 10627 (cyclo(Met-Asp-Trp-Phe-Dap-Leu)cyclo(2b-5b)), bears a lactam bridge between the side chains of two amino acids and presents, therefore, a bicyclic structure which contains two consecutive b-turns Pavone et al., 1995a,b) .
MEN 10627 is markedly more potent than L-659-877, both in vitro and in vivo and possesses a much longer duration of action in vivo . Despite these favourable characteristics, the chemical-physical properties of MEN 10627 hampered its further development as a drug candidate. Aiming at an improvement of the hydrophilicity of MEN 10627 without altering its pro®le of action as an NK 2 receptor antagonist, we synthesized MEN 11420, or cyclo {[Asn(b-D-GlcNAc) -Asp-Trp-Phe-Dap -Leu]cyclo(2b-5b)} (Figure 1 ), a bicyclic peptide bearing a (2-acetylamino-2desoxy-b-D-glucopyranosyl)-L-asparaginyl residue in the place of the Met residue present in MEN 10627. The introduction of a glycosyl residue to increase solubility and bioavailability of peptides is an approach that has been already used in our laboratory (Pinzani et al., 1996) , and glycopeptide analogues of substance P (SP) and of NKA receptor antagonists have been described by others (Haro et al., 1990; Holzemann et al., 1994) . The sugar moiety present in MEN 11420 lends it an about 80 fold increase in water solubility as compared to MEN 10627. The aim of the present study was to describe the in vitro and in vivo pharmacology and the radioligand binding pro®le of MEN 11420, in comparison with the parent peptide.
Methods

Binding assays
CHO cells transfected with the human NK 2 receptor were provided by Dr J.E. Krause (Washington University, School of Medicine, St. Louis, MO). Con¯uent cells from 4 Petri dishes were harvested in phosphate buered saline, pelleted by centrifugation at 2006g (48C) and homogenized with a Polytron PT3000 (Kinematica) at 13,000 r.p.m. for 15 s, in 20 ml of 50 mM Tris-HCl buer, pH 7.4, containing bacitracin (0.1 mg ml 71 ), chymostatin (0.01 mg ml 71 ), leupeptin (0.005 mg ml 71 ) and 10 mM thiorphan (buer A). The homogenate was centrifuged for 1 h at 25,0006g (48C) and the pellet resuspended in the binding buer, composed of buer A supplemented with 150 mM NaCl, 5 mM MnCl 2 and 0.1% bovine serum albumin, at a protein concentration of about 0.35 mg ml 71 (Lowry et al., 1951) . The membranes (30 ± 50 mg protein/assay) were incubated for 30 min at 208C with: (a) 100 pM [ 125 I]-NKA and various concentrations (0.01 nM ± 1 mM) of cold NKA (saturation experiments, in the absence or in the presence of 0.3, 3, 30 nM MEN 11420) or 10 dierent concentrations (0.01 nM ± 10 mM) of the competing compounds (competition experiments) or (b) 8 dierent concentrations of [ 3 H]-SR 48968 (0.01 ± 10 nM) (saturation experiments, in the absence or in the presence of 0.3, 3, 30 nM MEN 11420) or 0.6 nM [ 3 H]-SR 48968 and 10 dierent concentrations (0.01 nM ± 10 mM) of the competing compounds (competition experiments), in a ®nal volume of 0.5 ml. All the experiments were performed in duplicate or triplicate; 1 mM unlabelled NKA or 1 mM SR 48968 were used for de®ning nonspeci®c binding, when [ 125 I]-NKA or [ 3 H]-SR 48968 were used as radioligands, respectively. The reaction was terminated by the addition of 4 ml of ice-cold 50 mM Tris-HCl buer, pH 7.4, followed by rapid ®ltration through Whatman GF/B ®lter sheets (presoaked in 0.5% bovine serum albumin for at least 3 h) with a Brandel cell harvester. The ®lters were washed three fold with 4 ml of the same ice-cold buer. The trapped radioactivity was determined by use of a g-counter (Cobra, Canberra-Packard) or a b-scintillation counter (2200 CA, Canberra-Packard).
Furthermore, the binding anity of MEN 11420 for a range of 43 dierent receptors, including NK 1 and NK 3 receptors, and for Na + , Ca 2+ and K + channels (see Results) was measured, according to established methods, at Cerep (le Bois l'Eveque BP, 186600 Celle l'Evescault, France).
Organ bath studies
Male albino New Zealand rabbits (2.5 ± 3.0 kg), male Syrian golden hamsters (100 ± 120 g), male albino guinea-pigs (250 ± 300 g) and male albino rats (Wistar strain, 300 ± 350 g) were stunned and bled. Guinea-pig ileum longitudinal muscle myenteric plexus strips, rabbit pulmonary artery circular muscle strips deprived of the endothelium, rings of hamster trachea, rat urinary bladder longitudinal muscle strips and rat portal veins were prepared for recording of mechanical responses to tachykinin receptor agonists in oxygenated Krebs solution, as described in previous studies from our laboratory (Maggi et al., 1990; Patacchini et al., 1991; . Furthermore, longitudinal detrusor muscle strips from the mouse urinary bladder were prepared from male albino mice (Swiss, CD-1 strain). All preparations were placed in 5 ml organ baths ®lled with oxygenated (96% O 2 and 4% CO 2 ) Krebs solution of the following composition (mM): NaCl 119, NaHCO 3 25, KH 2 PO 4 1.2, MgSO 4 1.5, CaCl 2 2.5, KCl 4.7 and glucose 11.
The mechanical activity of guinea-pig ileum (load 3 mN), rat urinary bladder (load 5 mN) rat portal vein (load 3 mN) and mouse urinary bladder (load 5 mN), was recorded isotonically, while that of rabbit pulmonary artery and hamster trachea (load 10 mN each) was recorded isometrically.
The activity of MEN 11420 at tachykinin NK 1 receptors was evaluated in the guinea-pig ileum (in the presence of atropine and chlorpheniramine, 1 mM each, and of indomethacin, 3 mM) and in the rat urinary bladder (in the presence of indomethacin, 10 mM), by using [Sar 9 ]substance P (SP) sulphone and septide (pGlu-Phe-Phe-Pro-Leu-Met-NH 2 ) as tachykinin NK 1 receptor selective agonists.
The activity of MEN 11420 at tachykinin NK 2 receptors of the rabbit pulmonary artery, hamster trachea and mouse urinary bladder, that are essentially monoreceptorial preparations was evaluated against NKA as the agonist. The eect of MEN 11420 at NK 2 receptors of the rat urinary bladder was studied by using [bAla 8 ]NKA(4 ± 10) (Rovero et al., 1989) as an NK 2 receptor-selective agonist, and in the presence of the NK 1 receptor-selective antagonist SR 140333 (Emonds-Alt et al., 1993) (0.1 mM) to occlude the tachykinin NK 1 receptors in this preparation (Burcher & Buck, 1986; Maggi et al., 1988) .
The activity of MEN 11420 at tachykinin NK 3 receptors was evaluated in the guinea-pig ileum and in the rat portal vein, by using senktide (succ-[Asp 6 , MePhe 8 ]SP(6 ± 11)) as a tachykinin NK 3 receptor selective agonist. Atropine was not added to the medium of the guinea-pig ileum, at variance with the conditions used for studying responses mediated by the NK 1 receptor, since stimulation of prejunctional NK 3 receptors in this preparation promotes the release of acetylcholine from cholinergic nerves (Laufer et al., 1988) which, in turn, determines contraction via muscarinic receptors placed on smooth muscle. In these experiments SR 140333 (0.1 mM) was present in the medium, to rule out any involvement of NK 1 receptors.
In all preparations tested, cumulative concentrationresponse curves to the agonists were obtained, each concentration being added when the eect of the preceding one had reached a steady state. Only one concentration of antagonist was tested in each individual preparation. The preparations were challenged with the ®rst concentration of agonist after a preincubation period of 15 min with MEN 11420. When timedependence of the antagonist eect was investigated (i.e. with hamster trachea and mouse urinary bladder), a prolonged (120 min) preincubation period was also used.
The reversibility of MEN 11420-induced NK 2 receptor blockade was evaluated in the hamster trachea and mouse urinary bladder as follows: NKA (0.1 mM) was administered to the preparations at 30 min intervals, until reproducible contractile responses were obtained (generally after 2 ± 3 administrations). At this time MEN 11420 was added to the bath solution, 15 min before the next challenge with the agonist. The preparations were then thoroughly washed with Krebs solution, which was renewed every 5 min. Administration of the agonist was repeated 30, 60 and 90 min after washout of the antagonist, and the responses were compared to those obtained in control time-matched preparations.
In vitro stability tests
Blood was collected, by cardiac puncture from ether anaesthesized rats, into heparin-treated tubes and plasma was obtained by centrifugation. The liver, the kidneys and about 40 cm of small intestine were removed, rinsed in saline and immediately homogenized, with a Polytron PT 3000 (Kinematica, Lucerne, Switzerland) homogenizer, in 9 volumes of 50 mM phosphate buer, pH 7.5. To prepare the microsomal fraction, the liver was homogenized in 4 volumes of the buer and centrifuged at 90006g for 30 min; then the supernatant was centrifuged for 60 min at 105,0006g and the pellet was resuspended in two volumes of the buer. The antagonists were added to the homogenates or to the microsomal suspension (with or without 1 mM NADPH) at the ®nal concentration of 5 mM. Mixtures were incubated at 378C and, after 6 h (1 h with microsomes), 50 ml samples were deproteinized with 250 ml of acetonitrile, vortex-mixed and centrifuged at 2,0006g for about 5 min. Two hundred microliters of the supernatant were evaporated to dryness under an air stream, the residue was dissolved in 100 ml of distilled water and 20 ml were subjected to high performance liquid chromatagraphic (h.p.l.c.) analysis for the determination of unchanged compounds. The h.p.l.c. system consisted of a model 465 autosampler (Kontron Instruments S.p.A., Milan, Italy) and a model LC-9A pump (Shimadzu Co., Kyoto, Japan) connected to a Nucleosil 100 C18 reversed-phase column (15064.6 mm, particle size 5 mm, Knauer, Berlin, FRG) protected by its precolumn. Eluting peaks were detected by a¯uorescence spectrophotometer (650-10S, Perkin Elmer-Hitachi, Tokyo, Japan; l ex =280 nm and l em =350 nm) and measured by the Class LC-10 software (Shimadzu) on a model ProLinea 3/25s Compaq personal computer. The composition of the mobile phase was: water/acetonitrile/methanol (each containing 0.1% TFA) in the ratio 60/30/10 v/v, for the analysis of MEN 11420, and 50/40/10 v/v, for the analysis of MEN 10627. The¯ow rate was set at 1 ml min 71 .
In vivo studies
Male albino rats Wistar strain (Charles River, Calco, Italy), weighing 340 to 400 g, were anaesthetized with urethane (1.2 g kg 71 , s.c.). The right jugular vein was cannulated for i.v. administration of drugs. The urinary bladder was cannulated by the transurethral route and ®lled with 0.5 ml of saline. The pelvic ganglia were bilaterally removed to exclude indirect components in the response to the agonists. The ureters were ligated in the middle region to keep constant the bladder volume.
In a ®rst series of experiments the activity and selectivity of MEN 11420 (100 nmol kg 71 , 10 min before) was determined by checking its eect toward bladder contractions induced by i.v. administration of submaximally (50 ± 60% of E max ) and maximally eective doses (see results) of the NK 1 and NK 2 receptor selective agonists [Sar 9 ]SP sulphone and [bAla 8 ]N-KA(4 ± 10), respectively. To exclude the possibility that high doses of [bAla 8 ]NKA(4 ± 10) may be acting in part by stimulation of NK 1 receptors, SR 140333 (1 mmol kg 71 , i.v.) was administered 10 min before the ®rst dose of the agonist.
In a second series of experiments, a submaximally eective dose of [bAla 8 ]NKA(4 ± 10) (1 nmol kg 71 , i.v.) was used, as described previously , to determine the NK 2 receptor blocking activity of MEN 11420 after various routes of administration as well as its duration of action. Brie¯y, 3 or more reproducible control responses to the agonist were elicited at 20 ± 30 min intervals, then MEN 11420 was administered by the intravenous, intranasal, intrarectal or intraduodenal route. The challenge with the agonist was repeated at 20 ± 30 min intervals starting 5 min after and up to 210 min from antagonist administration.
For intravenous administration, MEN 11420 was administered in saline in a volume of 0.1 ml kg 71 . For intranasal administration MEN 11420 was dissolved in saline: a total volume of 0.1 ml kg 71 was administered divided in 2 equal amounts applied to each nostril by means of a 50 ml Hamilton microsyringe, as described previously . For intrarectal administration the rectum was emptied of the foecal pellets by an enema of 1 ml bidistilled water, then a needle for intragastric gavage (7.5 cm long) was inserted into the rectum for about 7 cm to allow the administration of the compound in a volume of 0.1 ml kg 71 . For intraduodenal administration, the antagonist was injected in a volume of 1 ml kg 71 into the proximal duodenum at about 2 cm from the pyloric sphincter.
In all experiments, vehicle-treated rats served as controls. The contractile responses were calculated as the area under the curve by using a Mini Mop apparatus (Kontron, Germany) and expressed as % variation of the control response to the agonist at various times.
Statistical analysis
All values in the text, tables or ®gures are means+95% con®dence limits, or +s.e.mean. Statistical analysis was performed by means of Student's t test for paired or unpaired data or by means of two-way analysis of variance (ANOVA), followed by Dunnett's test for multiple comparisons, when applicable. A P level 50.05 was considered statistically signi®cant.
Competition (K i ) and saturation (K D , B max ) data were analysed by EBDA/LIGAND, a nonlinear iterative ®tting program (McPherson, 1985) . Statistical analysis was made by using the computer programme InStat for Macintosh (GraphPad Software).
For organ bath experiments, the competitive nature of antagonism was checked by the Schild analysis. Antagonists providing plots with linear regression lines and slopes not signi®cantly dierent from unity were considered competitive. The anity of competitive antagonists was expressed in terms of pK B (negative logarithm of the antagonist dissociation constant), estimated according to the equation: pK B =log 10 [dose-ratio71]7log 10 [antagonist concentration], assuming a slope value of 71 (Kenakin, 1993; Jenkinson, 1991) .
In the hamster trachea and mouse urinary bladder MEN 11420 caused nonparallel rightward shifts of the concentration-response curves to NKA, and decreased the E max . Thus, the anity of MEN 11420 for NK 2 receptors in these preparations was estimated by the double-reciprocal plot method described by Kenakin (1993) For in vivo experiments stock solutions of MEN 11420 (1 mM) were prepared in saline. [bAla 8 ]NKA(4 ± 10) was dissolved in DMSO (3 mM), then diluted in DMSO for the dose-response curve (volume of injection 0.1 ml kg 71 ) or in saline for the repeated single-dose protocol (volume of administration 1 ml kg 71 ).
Results
Binding at the human NK 2 receptor in transfected CHO cells Competition experiments MEN 11420 showed high anity for the human NK 2 receptor expressed in CHO cells, with the same K i value whatever the radioligand. Its anity was comparable with that of MEN 10627, when [ 3 H]-SR 48968 was used, and only about four fold lower than that of the parent peptide with [ 125 I]-NKA as the radioligand (Table 1) .
Saturation experiments MEN 11420 concentration-dependently increased the K D of either [ 125 I]-NKA or [ 3 H]-SR 48968, without signi®cantly aecting the B max (Tables 2 and 3, Figure  2 ), a behaviour appropriate for a competitive ligand.
Receptor selectivity and ion channel binding anity The anity of MEN 11420 was measured at a variety of tachykinin and non-tachykinin receptors and of ion channels. MEN 11420 showed negligible binding anity (pIC 50 56.0) at NK 1 and NK 3 , B 1 and B 2 , bombesin, calcitonin gene-related peptide (CGRP), CCK A and CCK B , a 1 and a 2 , b 1 and b 2 , D 1 and D 2 , ET A and ET B , GABA A and GABA B , galanin, AMPA, kainate, NMDA, glycine, H 1 , H 2 , H 3 , muscarinic, NPY, neurotensin, nicotinic, opiate, PCP, P 2X , P 2Y , 5-HT 1A , 5-HT 1B , 5HT 1D , 5-HT 2A , 5-HT 3 , 5-HT 4 , s, somatostatin and VIP receptors. Nor had MEN 11420 (1 mM) measurable anity for Na + (site 1 and 2), Ca 2+ (L and N types) or K + (ATP-, voltage-and Ca 2+ -dependent) channels (data not shown).
Organ bath experiments
Eect of MEN 11420 at tachykinin NK 2 receptors in isolated organs from various species The mouse isolated urinary bladder is a preparation in which tachykinins produce a contraction by exclusive stimulation of NK 2 receptors. Neither the NK 1 receptor selective agonists, [Sar 9 ]SP sulphone and septide (1 mM each), nor the NK 3 receptor selective agonist senktide (1 mM) produced responses in this mouse tissue (n=4 for each agonist), while NKA induced concentrationdependent contraction (EC 50 =55 nM (95% c.l.=47 ± 65), n=18) ( Figure 3 ). After equilibration (1 h), the concentration-response curve to NKA was reproducible over an experimental period of at least 4 h if elicited at 1 h interval with intervening washout. Up to 10 mM, MEN 11420 did not produce agonist eects in any of the bioassays tested (rabbit pulmonary artery, hamster trachea, rat urinary bladder, mouse urinary bladder, guinea-pig ileum and rat portal vein). MEN 11420 produced a concentration-dependent rightward shift of the log concentrationresponse curve to the agonist in the rabbit pulmonary artery and in the rat urinary bladder without inducing depression of E max : in both preparations, Schild plot was compatible with competitive antagonism at tachykinin NK 2 receptors (Figure 4) .
In the hamster trachea and mouse urinary bladder MEN 11420 produced a concentration-dependent non parallel rightward shift of the curve to the agonist while depressing E max (Figure 3 ). To investigate whether the observed insurmountable antagonism could result from an irreversible interaction with hamster or mouse NK 2 receptors, we evaluated the reversibility and the time-dependence of the receptor blockade induced by MEN 11420 in these preparations. As shown in Figure 5 , the inhibition exerted by MEN 11420 (10 nM, 15 min incubation) on the response produced by NKA (100 nM) in the hamster trachea was fully and quickly reversed by washout. Neither the E max of NKA nor the extent of the rightward shift of the curve to NKA were signi®cantly modi®ed by prolonging the incubation of MEN 11420 (3 nM) from 15 to 120 min, respectively ( Figure 5 ).
In the mouse urinary bladder the inhibition exerted by MEN 11420 (10 nM, 15 min incubation) on the response produced by NKA (100 nM) was slowly but fully reversed by washout ( Figure 5 ). Prolonging the contact time of MEN 11420 from 15 to 120 min slightly increased the antagonist potency of MEN 11420 ( Figure 5 ).
Since the insurmountable antagonism exerted by MEN 11420 in the hamster trachea and mouse urinary bladder is not a consequence of an irreversible interaction with hamster or mouse NK 2 receptors, the apparent pK B values for the above receptors were estimated by the double-reciprocal plot method (see Methods). The data shown in Table 4 Eect of MEN 11420 at tachykinin NK 1 and NK 3 receptors Data shown in Figure 6 and Table 5 , indicate that MEN 11420 produces a weak competitive antagonism (pK B 56) toward NK 1 receptor-mediated contractions in the guinea-pig ileum when either septide or [Sar 9 ]SP sulphone were used as agonists. When assayed at rat NK 1 receptors of the rat urinary bladder, MEN 11420 (10 mM) showed no appreciable antagonism toward septide-or [Sar 9 ]SP sulphone-induced contractions ( Table 5 ).
In the guinea-pig ileum preparation set up for recording NK 3 receptor-mediated responses to tachykinins (senktide as agonist, SR 140333 present in the medium) MEN 11420 produced a weak (pK B 56) competitive antagonism of the response to senktide (Table 5; Figure 6 ). Up to 10 mM MEN 11420 failed to antagonize senktide-mediated contractions in the rat portal vein (Table 5 ).
In vitro stability tests
MEN 11420 was remarkably stable to enzymatic degradation in all the media tested, since less than 10% of the added compound was lost at the end of both a 6 hincubation with enzymes in plasma and rat tissue homogenates, and a 1 h-incubation with cytochrome P450 oxygenases in liver microsomes (Table 6 ). On the other hand, MEN 10627, which resisted the hydrolytic activities present in rat plasma and kidneys homogenate, was slowly degraded by liver and small intestine homogenates and by the hepatic NADPH-dependent microsomal enzymes, with a loss of up to 70% of the original amount at the end of the incubation periods (Table 6 ).
In vivo experiments
In an initial series of experiments we used a submaximal and a maximal dose of the NK 1 and NK 2 receptor selective agonists, [Sar 9 ]SP sulphone and [bAla 8 ]NKA(4 ± 10), respectively, to produce contraction of the rat urinary bladder in vivo and to verify the eectiveness and selectivity of MEN 11420 (100 nmol kg 71 , i.v., 10 min before) as an NK 2 receptor antagonist. A maximally eective dose of [Sar 9 ]SP sulphone (10 nmol kg 71 , i.v.) and [bAla 8 ]NKA(4 ± 10) (300 nmol kg 71 , i.v.) increased bladder pressure by 58+3 and 46+7 mmHg, respectively (n=5). Ten minutes after the administration of MEN 11420 (100 nmol kg 71 , i.v.) the response to [Sar 9 ]SP which produced a response of 12.9+0.9 mmHg (n=84), approximately 30% of the maximal response at 300 nmol kg 71 , was selected: this response did not show signi®cant variations up to 210 min from the vehicle (saline) administration. Intravenous administration of MEN 11420 (0.3 ± 10 nmol kg 71 ) produced a dose-dependent inhibition of the responses of the rat urinary bladder to [bAla 8 ]NKA(4 ± 10) (Figure 7a ). MEN 11420 showed a long duration of action: no sign of recovery was observed up to 210 min from administration of MEN 11420 at doses of 1 ± 10 nmol kg 71 . When these data were compared with those obtained with MEN 10627 in the same model , MEN 11420 appeared to be about 10 fold more potent than its parent compound and to possess a longer duration of action: as an example, 1 nmol kg 71 MEN 11420 produced 460% inhibition of the response to the agonist, and no fading was evident up to 210 min. In contrast, a 10 nmol kg 71 MEN 10627 was required to produce a Each value is presented as the means+s.e.mean (n=9 ± 12) of pK B , (negative logarithm of the antagonist dissociation constant) calculated from the Schild plot in the evidence of competitive antagonism or a by the double reciprocal plot method (see Methods) for noncompetitive or pseudoirreversible antagonism. b The data are from Maggi et al. (1994) .
comparable inhibitory eect which lasted only up to 120 min from i.v. administration of the antagonist . As shown in Figure 7 , MEN 11420 was active at inhibiting urinary bladder contractions induced by i.v. [bAla 8 ]NKA(4 ± 10) also after intranasal, intrarectal and intraduodenal administration. A signi®cant inhibitory eect towards the response of the agonist was produced by MEN 11420 at doses of 3 ± 10, 30 ± 100 and 100 ± 300 nmol kg 71 after intranasal, intrarectal and intraduodenal administration, respectively. For all these three routes of administration, the onset of the blockade was slow (60 ± 120 min to peak inhibition) and the activity was sustained (little or no sign of recovery of the response to the agonist up to 210 min from antagonist administration). Again, a comparison with MEN 10627 indicates a marked improvement of in vivo activity of MEN 11420 after intranasal and intraduodenal administra-tion. For example, after intranasal administration, doses of 10 and 100 nmol kg 71 of MEN 11420 and MEN 10627 were, respectively, required to produce similar inhibition (about 80%) of the response to the agonist. Moreover, whilst the eect of MEN 11420 showed no fading up to 210 min from its intranasal administration (Figure 7b ), the eect of MEN 10627 showed a signi®cant fading at 4120 min from its administration . Each value is the mean+s.e.mean (n=9 ± 12) of pK B (negative logarithm of the antagonist dissociation constant). NK 1 receptorselective agonists used in the guinea-pig ileum were a septide, b [Sar 9 ]SP sulphone and c SP methylester. d Data are from Maggi et al. (1994) . e NV: insurmountable antagonism, pK B not valid. The improved in vivo activity of MEN 11420 was even more evident after intraduodenal administration: a long lasting 50% inhibitory eect of MEN 11420 was observed at the dose of 100 nmol kg 71 (Figure 7d ). In the same assay, MEN 10627 was shown to need a dose of 3 mmol kg 71 to produce an inhibition of about 40%, the activity being no longer signi®cant beyond 180 min from antagonist administration .
Discussion
The present ®ndings demonstrate that the modi®cations on the side chain of the Met residue of MEN 10627 , with the introduction of a glycosylated moiety, do not markedly aect the potency as a tachykinin NK 2 receptor antagonist in vitro. Both MEN 10627 and MEN 11420 are potent NK 2 receptor antagonists, yet the latter compound showed more favourable chemical-physical characteristics, as demonstrated by the increase (about 80 fold) in water solubility. Also the good selectivity of the compound was preserved following the introduction of the glycosylated moiety: the anity of MEN 11420 for rat NK 2 receptors (pK B =9.0) was about 4 orders of magnitude higher than for rat NK 1 or NK 3 receptors, a pro®le similar to that of MEN 10627. MEN 11420 showed no detectable binding anity for a large number of non-tachykinin receptors and ion channels. This characteristic distinctly separates this class of compounds from non-peptide tachykinin receptor antagonists, such as SR 48968, which possesses sizeable anity for m opioid receptors (Martin et al., 1992; Boyle et al., 1993) and local anaesthetic-like activity (Wang et al., 1995) . It appears likely that the highly constrained backbone of MEN 10627 and MEN 11420 (Pavone et al., 1995a,b) which is optimized for interacting with NK 2 receptors, does not easily enable it to ®t into other binding sites. A similar explanation may, at least in part, account for the resistance to metabolic degradation showed by MEN 10627 and, especially, MEN 11420. The absence of measurable in vitro metabolism for the latter compound may be also related to the substitution of the oxidable methionine residue present in MEN 10627.
MEN 11420 exerted a competitive type of interaction at human NK 2 receptors transfected in CHO cells when either a peptide agonist (NKA) or a nonpeptide antagonist (SR 48968) was used as a radioligand. A partial overlapping between the binding sites of the parent compound MEN 10627 and SR 48968 is suggested by the observation that co-incubation of these antagonists prevents the depressant eect of SR 48968 on the attainment of E max to the agonist in functional assays . Clearly a mutational mapping analysis of the NK 2 receptor is required to establish to what extent a peptide derived antagonist, such as MEN 11420, could share the binding site(s) of natural agonist and nonpeptide antagonist on the human NK 2 receptor.
Similar to many other tachykinin receptor antagonists of peptide and non-peptide nature (Maggi et al., 1990; 1993) , MEN 11420 also displayed remarkable dierences in anity for NK 2 receptors expressed in dierent species. The molecular basis for these dierences has not yet been ascertained, although they probably originate from species-dependent variations at nonconserved positions in the primary sequence of the NK 2 receptor protein. Notably, the pattern of speciesdependent variable anities of MEN 11420 does not dier from that of MEN 10627, further suggesting that the sugar moiety introduced in MEN 11420 does not directly interact with the receptor.
Interestingly, MEN 11420 produced a clearcut depression of the E max to the agonist in the hamster trachea and mouse urinary bladder assays: this behaviour occurs in preparations in which an exceedingly high anity of the ligand for NK 2 receptors has been measured (apparent pK B =10.2 and 9.8) and its origin is uncertain. It has to be noted that a competitive behaviour has been observed for MEN 10627 in the hamster trachea assay , which is dierent from the noncompetitive behaviour observed for MEN 11420: it is possible that the dierent structure of the two antagonists dierentially interacts with the microenvironment of the cell membrane in the surroundings of the NK 2 receptor. While further studies are needed to address this issue by, for example, investigating the pattern of glycosylation of the NK 2 receptor in dierent species, we can exclude the possibility that an irreversible interaction with the receptor had occurred, since depression of the response to the agonist by MEN 11420 was fully reversible upon washout in both hamster trachea and mouse urinary bladder.
The most striking pharmacological advantages of MEN 11420 over MEN 10627 were evident in vivo: the two compounds have similar anities for NK 2 receptors in the rat urinary bladder smooth muscle (pK B 9.0 and 8.8, respectively) yet, after intravenous administration, MEN 11420 was about 10 fold more potent than MEN 10627 in inhibiting the contraction produced by the NK 2 receptor selective agonist and its blocking activity had a longer duration of action than that of MEN 10627. The improved pattern of in vivo antagonist activity relates to a more persistent presence of MEN 11420 in plasma, as compared to MEN 10627 (unpublished data), which, in turn, is probably related to the more favourable chemical physical characteristics and to the lower liability to metabolic elimination. Moreover, despite the increase in molecular size (m.w. 947 and 761 for MEN 11420 and MEN 10627, respectively) the improvement of in vivo activity was also evident after intranasal and intraduodenal administration of the compounds, indicating that the presence of the sugar moiety in MEN 11420 increases bioavailability. On comparison of the doses required to produce inhibition of the urinary bladder contraction in response to an NK 2 receptor agonist after intraduodenal administration in anaesthetized rats, MEN 11420 appeared to be about 30 fold more potent than MEN 10627 and about 10 fold more potent than the nonpeptide antagonist SR 48968 (see Maggi et al., 1994) . In those studies, MEN 10627 had been administered in 5% carboxymethylcellulose/4% Tween 80, because of its very poor water solubility, but the dierence in vehicle cannot account for the greater bioavailability of MEN 11420, since its eects after intraduodenal administration are not changed if it is dissolved exactly as MEN 10627 (data not shown).
Despite its good activity after intraduodenal administration, higher doses of MEN 11420 are needed to produce blockade of the NK 2 receptors than after i.v. administration. This dierence was much less pronounced if the compound was administered by the intranasal route, indicating a very good systemic bioavailability following this route of administration. The nasal mucosa has proven to be the most promising, among absorptive mucosae investigated so far, for the delivery of peptide and protein-based drugs that are not readily available by the oral route (Sayani & Chien, 1996) . However, the presence of an active enzymatic barrier may sometimes reduce the practicability of this route (Sarkar, 1992) . The high bioavailability of nasally instilled MEN 11420, probably related to its low liability to enzymatic degradation, suggests that the intranasal route might be conveniently exploited for a noninvasive parenteral formulation of the compound for its clinical investigation.
In conclusion, the present ®ndings indicate that MEN 11420 is a potent and selective tachykinin NK 2 receptor antagonist, with a markedly improved pro®le of action compared to its lipophilic parent compound MEN 10627.
Owing to the combination of its in vitro and in vivo pharmacological properties MEN 11420 appears to be a very useful tool for probing the pathophysiological role of peripheral tachykinin NK 2 receptors in man.
